BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cairns EA, Szczesniak AM, Straiker AJ, Kulkarni PM, Pertwee RG, Thakur GA, Baldridge WH, Kelly MEM. The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. J Ocul Pharmacol Ther 2017;33:582-90. [PMID: 28719234 DOI: 10.1089/jop.2017.0037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Schurman LD, Lu D, Kendall DA, Howlett AC, Lichtman AH. Molecular Mechanism and Cannabinoid Pharmacology. Handb Exp Pharmacol 2020;258:323-53. [PMID: 32236882 DOI: 10.1007/164_2019_298] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Onofrychuk TJ, Cai S, McElroy DL, Roebuck AJ, Greba Q, Garai S, Thakur GA, Laprairie RB, Howland JG. Effects of the cannabinoid receptor 1 positive allosteric modulator GAT211 and acute MK-801 on visual attention and impulsivity in rats assessed using the five-choice serial reaction time task. Prog Neuropsychopharmacol Biol Psychiatry 2021;109:110235. [PMID: 33373679 DOI: 10.1016/j.pnpbp.2020.110235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Gado F, Meini S, Bertini S, Digiacomo M, Macchia M, Manera C. Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery. Future Med Chem 2019;11:2019-37. [PMID: 31517528 DOI: 10.4155/fmc-2019-0005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
4 Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol 2019;176:1455-69. [PMID: 29981240 DOI: 10.1111/bph.14440] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 26.3] [Reference Citation Analysis]
5 Leo LM, Abood ME. CB1 Cannabinoid Receptor Signaling and Biased Signaling. Molecules 2021;26:5413. [PMID: 34500853 DOI: 10.3390/molecules26175413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Alaverdashvili M, Laprairie RB. The future of type 1 cannabinoid receptor allosteric ligands. Drug Metab Rev 2018;50:14-25. [PMID: 29355038 DOI: 10.1080/03602532.2018.1428341] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
7 Miller S, Daily L, Ploss M, Greig I, Ross R, Rayana NP, Dai J, Sugali CK, Mao W, Straiker A. Evidence that cannabinoid CB1 receptors regulate intraocular pressure via two opposing mechanisms. Exp Eye Res 2020;200:108241. [PMID: 32941875 DOI: 10.1016/j.exer.2020.108241] [Reference Citation Analysis]
8 Lafreniere JD, Kelly MEM. Potential for endocannabinoid system modulation in ocular pain and inflammation: filling the gaps in current pharmacological options. Neuronal Signal 2018;2:NS20170144. [PMID: 32714590 DOI: 10.1042/NS20170144] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
9 Slivicki RA, Iyer V, Mali SS, Garai S, Thakur GA, Crystal JD, Hohmann AG. Positive Allosteric Modulation of CB1 Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward. Front Mol Neurosci 2020;13:54. [PMID: 32410959 DOI: 10.3389/fnmol.2020.00054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
10 Lu D, Immadi SS, Wu Z, Kendall DA. Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor. Acta Pharmacol Sin 2019;40:324-35. [PMID: 30333554 DOI: 10.1038/s41401-018-0164-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
11 Thapa D, Cairns EA, Szczesniak AM, Kulkarni PM, Straiker AJ, Thakur GA, Kelly MEM. Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation. Molecules 2020;25:E417. [PMID: 31968549 DOI: 10.3390/molecules25020417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
12 Garai S, Leo LM, Szczesniak AM, Hurst DP, Schaffer PC, Zagzoog A, Black T, Deschamps JR, Miess E, Schulz S, Janero DR, Straiker A, Pertwee RG, Abood ME, Kelly MEM, Reggio PH, Laprairie RB, Thakur GA. Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. J Med Chem 2021;64:8104-26. [PMID: 33826336 DOI: 10.1021/acs.jmedchem.1c00040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Garai S, Kulkarni PM, Schaffer PC, Leo LM, Brandt AL, Zagzoog A, Black T, Lin X, Hurst DP, Janero DR, Abood ME, Zimmowitch A, Straiker A, Pertwee RG, Kelly M, Szczesniak AM, Denovan-Wright EM, Mackie K, Hohmann AG, Reggio PH, Laprairie RB, Thakur GA. Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators. J Med Chem 2020;63:542-68. [PMID: 31756109 DOI: 10.1021/acs.jmedchem.9b01142] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
14 Polini B, Cervetto C, Carpi S, Pelassa S, Gado F, Ferrisi R, Bertini S, Nieri P, Marcoli M, Manera C. Positive Allosteric Modulation of CB1 and CB2 Cannabinoid Receptors Enhances the Neuroprotective Activity of a Dual CB1R/CB2R Orthosteric Agonist. Life (Basel) 2020;10:E333. [PMID: 33302569 DOI: 10.3390/life10120333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Laprairie RB, Bagher AM, Rourke JL, Zrein A, Cairns EA, Kelly MEM, Sinal CJ, Kulkarni PM, Thakur GA, Denovan-Wright EM. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model. Neuropharmacology 2019;151:1-12. [PMID: 30940536 DOI: 10.1016/j.neuropharm.2019.03.033] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]